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ABSTRACT The objectives of this study were to determine pharmacokinetic/pharma-
codynamic (PK/PD) indices of fluoroquinolones that minimize the emergence of re-
sistant Salmonella enterica serovar Typhimurium (S. Typhimurium) using in vitro dy-
namic models and to establish mechanisms of resistance. Three fluoroquinolones,
difloxacin (DIF), enrofloxacin (ENR), and marbofloxacin (MAR), at five dose levels and
3 days of treatment were simulated. Bacterial killing-regrowth kinetics and emer-
gence of resistant bacteria after antibacterial drug exposure were quantified. PK/PD
indices associated with different levels of antibacterial activity were computed.
Mechanisms of fluoroquinolone resistance were determined by analyzing target mu-
tations in the quinolone resistance-determining regions (QRDRs) and by analyzing
overexpression of efflux pumps. Maximum losses in susceptibility of fluoroquinolone-
exposed S. Typhimurium occurred at a simulated AUC/MIC ratio (area under the
concentration-time curve over 24 h in the steady state divided by the MIC) of 47 to
71. Target mutations in gyrA (S83F) and overexpression of acrAB-tolC contributed to
decreased susceptibility in fluoroquinolone-exposed S. Typhimurium. The current
data suggest AUC/MIC (AUC/mutant prevention concentration [MPC])-dependent se-
lection of resistant mutants of S. Typhimurium, with AUC/MPC ratios of 69 (DIF), 62
(ENR), and 39 (MAR) being protective against selection of resistant mutants. These
values could not be achieved in veterinary clinical areas under the current recom-
mended therapeutic doses of the fluoroquinolones, suggesting the need to reassess
the current dosing regimen to include both clinical efficacy and minimization of
emergence of resistant bacteria.
KEYWORDS efflux pumps, fluoroquinolone, global regulator, in vitro dynamic model,
mutant prevention concentration, PK/PD integration, Salmonella Typhimurium, target
mutation, acrAB-tolC, gyrA
Fluoroquinolones are synthetic antibacterial agents with broad-spectrum, concen-tration-dependent bactericidal activity against a wide range of pathogens (1). How-
ever, resistance of human and animal pathogenic bacteria to a wide spectrum of
antibacterial agents, including fluoroquinolones, is an increasing concern globally (2, 3).
Furthermore, overuse or inappropriate use of antibiotics in animals, especially food-
producing animals, can lead to transfer of bacterial resistance to humans via the food
chain (4).
A common method for assessing the efficacy of antibacterial drugs focuses on
evaluation of the effect of selected doses of the drug on the reduction in the total
bacterial number at the infection site, with less attention to the amplification of
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drug-resistant subpopulations of bacteria by selective pressure (5, 6). However, a
number of studies have accentuated the importance of a mutant prevention concen-
tration (MPC)-based dosing approaches to enhance the potency of antibiotics and
restrict the selection of resistant mutants (7, 8). Furthermore, in vitro dynamic models
that mimic antibacterial pharmacokinetics in vivo have been applied to bridge the gap
between static in vitro data and the dynamic time course profiles. These models have
been used to establish the relationship between fluoroquinolone exposure and emer-
gence of resistant bacteria in humans, as well as to compare the potential of different
drugs within the same class for restricting the selection of resistant mutants of bacteria
(7, 9).
The aim of this study was to apply the MPC and in vitro dynamic model-based
approaches to determine pharmacokinetic/pharmacodynamic (PK/PD) indices of fluo-
roquinolones that minimize the emergence of resistant Salmonella enterica serovar
Typhimurium. We chose to investigate S. Typhimurium because of its zoonotic signif-
icance and the high level of drug resistance reported for this organism across the globe
(10–12). Loss of susceptibility in laboratory and field S. Typhimurium isolates was
associated with inappropriate use of fluoroquinolones (12). We investigated veterinary
fluoroquinolones, including difloxacin (DIF), enrofloxacin (ENR), and marbofloxacin
(MAR), for two reasons: first, the risk of cross-resistance for fluoroquinolones has been
reported for both human and animal pathogens (3, 4, 13–15), and second, previous
studies have demonstrated differences among veterinary fluoroquinolones in their
activity and potential for selection of resistant mutants of bacteria (16). We further
investigated the major mechanisms of fluoroquinolone resistance, including target
mutations as well as the expression of the efflux pumps and global regulators, and
established the relationships between these mechanisms and reduction in fluoroquin-
olone susceptibility.
(Part of this study was presented at the 13th International Congress of the European
Association for Veterinary Pharmacology and Toxicology, 19 to 22 July 2015 [17]).
RESULTS
Antibacterial activity. The pharmacodynamic profile of FQs against S. Typhimurium
clinical isolates from pigs and a standard strain (ATCC 14028) were determined in vitro.
As shown in Table 1, ENR and MAR had comparable activity, which was higher than that
TABLE 1 Antibacterial activity of three fluoroquinolones against S. Typhimurium isolates
from pigs
Parameter and isolate type
Value (g/ml) for:
DIF ENR MAR
Clinical isolates (n) 16 16 16
MIC (g/ml)
Range 0.13–8 0.03–2 0.03–2
MIC50 1 0.25 0.13
MIC90 4 2 1
Ra (%) 31.25 12.50 6.25
MPC (g/ml)
Range 0.50–16 0.13–4 0.13–4
MPC50 2 0.50 0.50
MPC90 8 4 4
MPC/MIC
Range 4–8 4–8 4
(MPC/MIC)50 4 4 4
(MPC/MIC)90 8 8 4
ATCC 14028b
MIC 0.13 0.03 0.03
MPC 0.50 0.13 0.13
MIC/MPC 4 4 4
aR (%), percent resistance in clinical isolates using the breakpoint of ciprofloxacin from the CLSI (M100-S23).
bThe control strain used in the present study.
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of DIF. MPC50 and MPC90 concentrations were 4-fold (DIF) and 2-fold (ENR and MAR)
higher than the respective MIC50 and MIC90 values. These data suggested that ENR and
MAR have a slightly higher potency than DIF.
Kill-regrowth analysis. The time course of killing and regrowth of S. Typhimurium
incubated in the presence of one of the FQs at five different constantly changing
concentrations was evaluated (Fig. 1). The antimicrobial activities of DIF, ENR, and MAR
were evaluated at a range of AUC/MIC ratios (areas under the concentration-time curve
over 24 h in the steady state divided by the MIC), including those achievable at the
clinically recommended doses of all drugs, against S. Typhimurium. An increase in
AUC/MIC ratio resulted in a decrease in the numbers of surviving pathogens. The
intensity of the antimicrobial effect (IE) versus AUC/MIC plots shows differences among
the 3 FQs (Fig. 2). For example, at an AUC/MIC ratio of 125, which is the proposed
AUC/MIC target for predicting the activity of FQs (18), the IE of MAR was 55% and 29%
FIG 1 Time courses of killing and regrowth kinetics for S. Typhimurium strain exposed to a 72-h course of difloxacin (DIF), enrofloxacin
(ENR), and marbofloxacin (MAR). Values at the right side of each panel indicate the simulated AUC/MIC ratios and TMSW. Arrows indicate
fluoroquinolone dosing.
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greater than those of DIF and ENR, respectively, suggesting the greatest antimicrobial
effect of a given AUC/MIC ratio of MAR against S. Typhimurium.
Emergence of resistance. The MIC values measured after each dosing (at 24, 48,
and 72 h) were normalized to the initial (0 h) MIC, and the relationship between MIC
changes and simulated AUC/MIC or AUC/MPC ratios was analyzed by using a mathe-
matical equation. As shown in Fig. 3A, the maximum loss in susceptibility (about 8-fold
FIG 2 AUC/MIC-dependent antibacterial effect of difloxacin (DIF), enrofloxacin (ENR), and marbofloxacin
(MAR) against S. Typhimurium, fitted by equation 1. For DIF, Ymax  386.3, dx  2.617, and x0  0.5054
(R2  0.99); for ENR, Ymax  382.0, dx  2.462, and x0  0.4494 (R2  1); for MAR, Ymax  481.8, dx 
2.486, and x0  0.5196 (R2  0.97).
FIG 3 Changes in susceptibility of S. Typhimurium. (A) Effect of AUC24/MIC ratio (top) or AUC24/MPC ratio (bottom) on the susceptibility of S. Typhimurium
strains exposed to difloxacin (DIF), enrofloxacin (ENR), and marbofloxacin (MAR). Data were fitted by equation 2. (Top) For DIF, a  12.92, xc  1.85, and b 
0.18; for ENR, a  8.82, xc  1.8, and b  0.21; for MAR, a  7.32, xc  1.67, and b  0.18. (Bottom) For DIF, a  12.92, xc  1.25, and b  0.18; for ENR, a 
8.82, xc  1.19, and b  0.21; for MAR, a  7.32, xc  1.07, and b  0.18. (B) Resistance of S. Typhimurium related to the intensity of the antibacterial effect
(IE). Data were fitted by equation 2. For DIF, a  14.27, xc  2.05, b  0.0.22, and R2  0.76; for ENR, a  10.85, xc  2.03, b  0.26, and R2  0.60; for MAR,
a  6.63, xc  2.13, b  0.22, and R2  0.87. (C) Resistance of S. Typhimurium related to the simulated AUC24/MPC ratio (left) or Cmax/MPC ratio (right) of three
fluoroquinolones (3FQs; combined data). Data were fitted by equation 2. (Left) a  9.52, xc  1.20, and b  0.18; (right) a  9.81, xc  0.02, and b  0.21.
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MIC increase for MAR and 16-fold MIC increase for DIF and ENR), which is the central
point in the curve, was observed at AUC/MIC ratios of 47 (MAR; R2  0.98), 63 (ENR;
R2  0.62), and 71 (DIF; R2  0.83). No loss in susceptibility was observed at the lowest
(13, 18, and 20) and highest (211, 290, and 314) simulated AUC/MIC ratios for MAR, ENR,
and DIF. The estimated AUC/MPC values that may protect the selection of resistant S.
Typhimurium were 69 (DIF), 62 (ENR), and 39 (MAR). The IE-versus-resistance relation-
ship was also analyzed using equation 2. As shown in Fig. 3B, a bell-shaped function
describes this relationship, with the highest MIC increases observed at an IE value of 112
for DIF (range, 96 to 132; R2  0.76), 106 for ENR (range, 84 to 133; R2  0.60), and 134
for MAR (range, 119 to 151; R2  0.87).
Similar patterns of the AUC/MIC-dependent changes in the susceptibility of S.
Typhimurium to DIF, ENR, and MAR could allow establishment of a generalized rela-
tionship between MIC increase and AUC/MIC ratios of FQs. Therefore, combined data
for MIC changes over a 3-day course of FQ treatment with DIF, ENR, and MAR were
integrated with combined AUC/MPC and Cmax/MPC (the maximum concentration of
drug in serum divided by the MPC) values. As shown in Fig. 3C, no losses in suscepti-
bility were observed when the combined AUC/MPC ratio was 38.3 and the Cmax/MPC
ratio was 2.6. This AUC/MPC value was greater than the individual values for MAR
(1.4-fold) but less than that for DIF (1.8-fold) or ENR (1.6-fold).
Population dynamics of fluoroquinolone treatment. To ensure the residual
activity of the drugs during the experiment, bioassays were conducted using filtrates
taken from the culture medium, and MIC values of filtrates against the parent strain
were converted to real-time drug residues in continuous culture. As shown in Fig. 4A,
the MIC estimates of the filtrates slightly decreased with time. However, these values
were less (only by 1- to 3-fold) than the anticipated drug concentration at a rate equal
to the flow, suggesting density-dependent decay does not fully explain the failure of
the simulated FQ concentration to clear the bacteria in the continuous culture.
The number of biofilm-forming bacteria was estimated from washes of the culture
vessels before and after sonicating the vessels to release bacteria adhering to the walls.
As shown in Fig. 4B, both the total population and subpopulation of bacteria recovered
from the walls of the culture vessels were lower in cultures with drug, especially at the
highest AUC/MIC ratios (314, 290, and 211 h for DIF, ENR, and MAR) compared with
control cultures, suggesting AUC/MIC-dependent inhibition of biofilm formation in S.
Typhimurium.
In order to predict and replicate the population dynamics of the treated continuous
culture, a previously described mathematical model was used with hypothetical strains
after expanding the equation to include an emerging mutant subpopulation (19–21).
Figure 5C shows the changes in populations of the hypothetical weakly biofilm-forming
strain in the presence of density-dependent decay at the effective concentrations of the
FQ based on an AUC/MIC ratio for ENR of 63, AUC/MPC ratio for ENR of 62, and
AUC/MPC ratio for three FQs of 38. There was maximal loss in susceptibility (Fig. 4C,
left), similar to the continuous culture experiment (Fig. 1), whereas the selection of
resistance was low (Fig. 4C, middle and right). These simulations show FQ AUC/MIC
(AUC/MPC)-dependent anti-Salmonella activity similar to our earlier results, and the
activity against selection of resistant Salmonella between ENR and three FQs combined
was comparable.
Mechanisms of resistance. Mechanisms of resistance in clinical isolates and in
vitro-selected resistant mutants of S. Typhimurium were elucidated (Table 2). As the
highest fold increases in MICs were observed after repeat dosing, selections of repre-
sentative first-step mutants were made from cultures after the last dosing (72 h). Eight
to 32 mutant strains were recovered from selective plates. Five colonies per plate from
each dose level were selected for MIC determination. A representative colony showing
the highest stable MIC increases by repeat MIC determinations then was selected per
dose level for further phenotype and genotype assays. These isolates (designated
STM-D1, -D2, -D3, and -D4) from cultures with AUC/MPC ratios of 9 to 72, isolates from
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the MPC plates of MAR, as well as 6 to 31% of clinical isolates (Table 1) had increased
MICs (2- to 64-fold increases) for one or more of the FQs. MIC increases were transfer-
able between FQs. This is in accordance with our previous findings in which losses in
susceptibility of Escherichia coli exposed to one FQ were transferable to other FQs and
even to structurally unrelated drugs, partly due to activation of global drug efflux
pumps (16, 22). To confirm the contribution of efflux pump activity to this resistance,
MICs were assessed in the presence of the efflux pump inhibitor phenylalanine-
arginine--naphthylamide (PAN). The MICs of the three FQs decreased by 2- to 8-fold
in the presence of PAN, indicating the involvement of efflux pumps for the observed
resistance. Therefore, overexpression of the efflux transporter gene and global regula-
tors was further evaluated by quantitative reverse transcription-PCR (RT-PCR). As shown
in Fig. 5A, expression of acrAB-tolCmRNA increased in isolates STM-D2 and -D3 exposed
to FQ AUC/MPC ratios of 6.7 and 13.2 (P  0.05), while no drug exposure-related
differences in acrAB-tolC expression were observed in isolates STM-D1, -D4, and -D5
FIG 4 Population dynamics of fluoroquinolone treatment. (A) Bioassay estimates of the MICs of DIF, ENR, and MAR during 3-day continuous culture. The culture
medium was taken from the central vessel every 4 h. After removing the bacteria through filtration, MIC values were checked with the S. Typhimurium standard
strain. LO, fluoroquinolone treatment with AUC/MIC ratio of 53 to 78; HI, fluoroquinolone treatment with AUC/MIC ratio of 211 to 314. (B) Biofilm formation
of S. Typhimurium following daily dosing with difoxacin, enrofloxacin, or difloxacin. At the end of the experiment (72 h), the culture vessel compartments were
separated, and biofilm strains in the vessel were washed and suspended with PBS or MHB II with or without sonication. Mean viable cell densities of bacteria
released from the walls of the culture vessels were counted. N/T, no antibiotic treatment; LO, treatment at AUC/MIC ratio of 53 to 78; HI, treatment with at
AUC/MIC ratio of 211 to 314; WO, the densities of bacteria in PBS following the third wash with PBS; P/S, the densities estimated in MHB II prior to sonication;
A/S-1 m or 30 m, the densities estimated in MHB II with sonication for 1 or 30 min. Three independent estimates of densities were made for each sample. (C)
Simulation of fluoroquinolone treatment with parameter A with 72 h of continuous culture of S. Typhimurium, showing changes in viable cell density with
fluoroquinolone concentration. A dose of ENR (AUC/MIC of ENR, 63 [left]; AUC/MPC of ENR, 62 [middle]; AUC/MPC of three fluoroquinolones, 38 [right])
administered every 24 h starting with a cell density of 108. Standard parameters and their definitions are as described in Levin and Udekwu (20), with the
following additions and changes in parameters: initA  8, 31, or 20 g; initN  1e8; initR  1; initD  0; init P  0; initB  0; initM (density of mutant
population)  0; psimax  1; psimin  2; psimaxp  0.001; psiminp  0.01; psimaxb  0.001; psiminb  0.00001; psimaxm (maximum growth
rate, mutant population)  1; psiminm  3; Mmin  1.875; Mmax  1.875; pd  0; cr  0.9; k  2.261; e  5e7; kr  0.25; kmax  1e7; w  3.9;
wb  0.0001; wm (flow rate of mutant population)  w; C  500; f  0; yp  0.0001; yd  0.00001; yb  0.000001; yw  0.0000001; ym (rate at which
mutations occur in NT)  0.000000001; ddx  0.01; dv  1e9; dk  1e9. A1, antibiotic decay; N1, density of viable planktonic sensitive bacteria; P1, density
of planktonic persistent bacteria; B1, density of the wall (biofilm) population; M1, density of mutant population; NT, total viable planktonic bacteria. The
simulation was run by the Berkeley Madonna program, accessed from http://www.eclf.net.
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exposed to FQ AUC/MPC ratios of 3.3, 26.3, and 52.7, respectively. Overexpression of
global regulatory genes was also significantly increased at 72 h in isolates from the
dynamic model, with AUC/MPC ratios of 6.7 and 13.2 increasing by up to 2- to 3-fold
(marA), 3- to 3.5-fold (soxS), 5- to 10-fold (ramA), and 6- to 7-fold (rob) compared to that
of the original strain, suggesting a positive correlation between gene expression of
acrAB-tolC and its regulators (Fig. 5B), and the expression of acrAB-tolC in the STM-D3
strain was similar to that in STM-isolate-15 (P  0.05), showing resistance (Fig. 5C).
Mutation in the quinolone resistance-determining regions (QRDRs) was also exam-
ined. Fully quinolone-susceptible strains had no mutations in the target genes. A single
gyrA mutation with S83F was present in in vitro-selected resistant isolates but not in
resistant clinical isolates (D87Y). No mutations were found in gyrB, parC, and parE in any
strains. Interestingly, in vitro-selected isolates showed multiple mechanisms of resis-
tance, including mutation and efflux pump overexpression, while in clinically resistant
isolates, resistance was mainly attributed to target mutation.
Relationships of MPC with pharmacokinetics. In vitro pharmacodynamic data
from the present study (MICs and MPCs) and published pharmacokinetic information of
the three FQs in pigs (AUC and Cmax) were integrated to evaluate whether PK/PD
indices by conventional dosing regimen of FQs agree with the protective AUC/MIC or
AUC/MPC ratios obtained in the present study (Table 3).
Based on Clinical and Laboratory Standards Institute (CLSI) breakpoints of cipro-
floxacin (23), the conventional dosing was shown to be effective for the susceptible, but
not intermediate and resistant, in vitro isolates. On the other hand, AUC/MIC and
Cmax/MIC ratios were not effective for the clinical isolates. In order to estimate an
MPC-based dosing regimen, AUC/MPC ratio, Cmax/MPC ratio, and T  MPC (the time
during which plasma concentrations exceed the mutant prevention concentration)
surrogates were analyzed. Analysis was performed to determine whether the conven-
tional doses of the three FQs could prevent the growth of the least susceptible
Salmonella first-step mutants. Our results showed that the order of potency of three
FQs against S. Typhimurium based on AUC/MPC ratios was MAR ENR DIF (Table 3).
While only MAR at the highest doses could achieve high levels of AUC/MPC50 ratios,
Cmax/MPC50 ratios, and T  MPC50, the AUC/MPC90 ratios and T  MPC90 of the three
FQs were below the protective values obtained here.
TABLE 2 Fluoroquinolone resistance phenotypes and amino acid substitutions in in vitro-
selected mutants and clinical isolates of S. Typhimurium
Strain
Fluoroquinolone MIC (g/ml)a Mutation
DIF DIFEPI ENR ENREPI MAR MAREPI gyrA gyrB parC parE
Parental strain
STM-st 0.13 0.03 0.03 0.03 0.03 0.03 WT WT WT WT
Single-step mutant from the
dynamic modelb
STM-D2 4 2 1.00 1 0.50 1 S83F WT WT WT
STM-D3 2 2 4 2 2 1 S83F WT WT WT
STM-D4 1.00 0.50 0.50 0.25 0.50 0.25 S83F WT WT WT
STM-D5 0.25 0.25 0.06 0.06 0.06 0.06 WT WT WT WT
Single-step mutant from
MPC plates
STM-mu-p1 1 0.25 0.50 0.25 0.50 0.25 S83F WT WT WT
Resistant clinical strains
STM-isol-2 0.25 0.06 0.06 0.03 0.03 0.03 WT WT WT WT
STM-isol-11 0.50 0.25 0.25 0.06 0.25 0.06 D87Y WT WT WT
STM-isol-15 4 0.5 2 0.25 2 0.25 D87Y WT WT WT
aThe MIC values were checked in the presence of 40 g/ml of Phe-Arg--naphthylamide (PAN), which is an
efflux pump inhibitor (EPI).
bRepresentative single-step mutants were selected randomly from the dynamic model with AUC/MPC ratios
of 6.7 (STM-D2), 13.2 (STM-D3), 26.3 (STM-D4), and 52.7 (STM-D5) with MAR.
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DISCUSSION
The in vitro dynamic model approach was applied to measure the activity of three
veterinary FQs against the emergence of resistance in S. Typhimurium. In the present
study, S. Typhimurium ATCC 14028 was used with consideration of its susceptibility and
its full genomic and phenotypic characterization.
The anti-Salmonella activities of the three FQs revealed an FQ-specific relationship
between IE and AUC/MIC ratios. This was in agreement with our previous findings using
FQs against E. coli and Actinobacillus pleuropneumoniae (16, 22, 24). Furthermore, the IE
showed species specificity that was lower (8 to 41%) than those from reports using
non-biofilm-forming bacteria, while it was similar to IEs of FQs against biofilm-forming
bacteria (difference of 8 to 10%) (16, 22, 24). The failure of FQs to suppress Salmonella
growth in the culture could result not only from resistant populations but also from
biofilm formation. However, the test strain used here was not a strong biofilm-forming
strain, suggesting the role of AUC/MIC ratio-dependent losses in susceptibility upon
continuous exposure to the FQs. The AUC/MPC value was suggested to be more
FIG 5 mRNA expression levels of efflux pump (A) and regulator genes (B) for in vitro isolates and clinical isolates (C) of S. Typhimurium. Strains were randomly
selected from the dynamic model treated with MAR at the end of the experiment (72 h). Strains D1 to D5 were isolated from cultures treated with AUC/MPC
ratios of 3.3, 6.7, 13.2, 26.3, and 52.7, respectively. Data represent the means  standard deviations from three independent experiments. Bars with different
letters (a to e) show significant differences between groups (P  0.05).
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accurate than the AUC/MIC value for the prevention of mutant selection, because the
MPC concept includes a mutant subpopulation (7). In the present study, AUC/MPC
ratios to reduce Salmonella-resistant mutants were 69 (DIF), 62 (ENR), and 39 (MAR).
These results were consistent with previous reports (22, 24). However, in the current
study, no difference of potency was found through conversion from AUC/MIC ratios to
AUC/MPC ratios resulting from different MPC/MIC ratios, because the MPCs of all 3 FQs
were 4 times higher than their respective MICs.
One interesting observation in this study was the differences in resistance mecha-
nisms between in vitro-selected resistant mutants and resistant clinical isolates:
mutation-dependent resistance (in vitro isolates) and efflux pump expression-
dependent resistance (clinical isolates). Similarly, previous studies had also indicated
that while field isolates or in vivo-selected mutants show small fold increases in MICs
and often a single gyrA mutation, S. Typhimurium experimental mutants selected in
vitro possess severalfold increases in MIC and multiple resistance mechanisms (25–27).
In Salmonella, single gyrA mutations, in either S83F or D87Y, were associated with
FQ-resistant isolates from humans and animals (10–12). Moreover, all field isolates
harbored a single gyrA mutation of D87Y, which shows a lower MIC than mutation of
S83F, while in vitro-selected resistance had an S83F mutation. Although no biochem-
TABLE 3 Pharmacodynamic predictors of fluoroquinolone activity based on integration of
pharmacokinetic/pharmacodynamic indices against S. Typhimurium clinical isolates
Parameters
Value for antibacterial agent
DIF
ENR
MARLow dose High dose
Pharmacokinetic parametersa
Dose (mg/kg) 5.00 2.50 10.00 2.00
AUC (g/ml) 32.12 6.82 10.07 10.95
Cmax (g/ml) 2.56 1.42 1.82 0.98
tmax (h) 1.32 4.99 3.79 2.11
t1/2 (h) 18.09 6.56 10.68 7.80
PK/PD integration based on MIC breakpointb
AUC/MICBPs 513.92 109.12 161.12 175.20
AUC/MICBPi 32.12 6.82 10.07 10.95
AUC/MICBPr 16.06 3.41 5.04 5.48
Cmax/MICBPs 40.96 22.72 29.12 15.68
Cmax/MICBPi 2.56 1.42 1.82 0.98
Cmax/MICBPr 1.28 0.71 0.91 0.49
PK/PD integration based on MIC of all
clinical isolatesc
AUC/MIC50 32.12 27.28 40.28 84.23
AUC/MIC90 8.03 3.41 5.04 10.95
Cmax/MIC50 2.56 5.68 7.28 7.54
Cmax/MIC90 0.64 0.71 0.91 0.98
PK/PD integration based on MPCs of
susceptible isolatesd
AUC/MPC50 32.12 27.28 40.28 43.80
AUC/MPC90 16.06 13.64 20.14 21.90
Cmax/MPC50 5.26 5.68 7.28 3.92
Cmax/MPC90 1.28 2.84 3.64 1.96
T  MPC50 (h) 24.59 20.36 38.37 15.37
T  MPC90 (h) 6.46 11.53 23.97 7.57
aDose, AUC, Cmax, tmax, and t1/2 were from published data (given in the text) from pharmacokinetic studies
of each fluoroquinolone in healthy pigs at the clinical dose.
bThe breakpoint of ciprofloxacin against all Salmonella species used was from the CLSI (M100-S23). BPs,
breakpoint for susceptible (0.06 g/ml); BPi, breakpoint for intermediate (0.12 to 1.0 g/ml); BPr,
breakpoint for resistant (2.0 g/ml).
cMICs of all clinical isolates from the present study were used.
dMPCs of fluoroquinolone-susceptible clinical isolates (MIC of 0.06 g/ml) from the present study were
used.
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istry was performed to confirm that this mutation conferred quinolone resistance, the
mutation conferring a substitution at S83F is more abundant than at D87Y in vitro.
It has been suggested that the overexpression of efflux pumps is a sufficient
condition for development of FQ resistance (28, 29). Furthermore, it has been reported
that in the absence of acrAB-tolC, S. Typhimurium was unlikely to select mutation under
ciprofloxacin pressure (30). In a resistant strain isolated from dynamic culture (STM-D3)
and a clinical isolate (STM-isol-15), increases (2.5- to 3-fold) in acrAB-tolC mRNA expres-
sion and gyrA mutation were found, whereas the susceptible isolates showed sup-
pressed acrAB-tolC gene expression and no gyrA mutation. These results indicate that
a dosing strategy based on AUC/MPC (39) was effective at preventing FQ resistance
due to suppression of efflux pump overexpression and target mutation. The transcrip-
tional activators, such asmarA, soxS, ramA, and rob, have been reported to play a critical
role in efflux pump activity in Salmonella (30–32). Consistent with this, there was a
positive correlation in expression levels of acrAB-tolC and each regulator in isolates
from an in vitro dynamic model in which downregulated efflux pump expression was
associated with suppressed global regulators.
The AUC/MIC ratio of 125 to 250 and Cmax/MIC ratio of greater than 8 to 10 were
suggested to be the target PK/PD indices associated with efficacy of FQ treatment (18).
Based on these endpoints, the three FQs could show high efficacy against susceptible
clinical isolates, with AUC/MIC and Cmax/MIC ratios of greater than 160 and 15,
respectively. However, these ratios had to be much lower to show efficacy against
strains with intermediate susceptibility. Moreover, we integrated our MPC data with the
AUC and Cmax values achievable at the clinically recommended doses of these drugs in
pigs (Table 3), and when these values were compared with the PK/PD predictions (Fig.
3) and the AUC/MPC ratio obtained from the present study, only MAR, with an
AUC/MPC50 ratio of 43.8, could achieve protection against the emergence of resistance
in susceptible clinical isolates of S. Typhimurium. These findings suggest the applica-
bility of the MPC-based dosing strategy for S. Typhimurium isolates only at higher doses
of these agents and a better in vitro activity of a given AUC/MIC (AUC/MPC) ratio of MAR
than those of DIF and ENR in terms of both antibacterial effect and prevention of the
selection of mutants.
There are limitations to the use of MPC-based dosing, including the different drug
concentration thresholds to restrict amplification of drug-resistant mutants depending on
inoculum size and the chance for selection of a two-step mutation (8). Moreover, while
MPC-based approaches can be useful to compare the abilities of FQs to prevent selection
of S. Typhimurium mutants, the results of higher clinical dose requirements should be
interpreted with caution, because inherently the in vitro MPC approach does not take into
account the synergistic role of the immune system for clearing infections in vivo (7).
In summary, our results confirmed an AUC/MIC-dependent antibacterial activity and
AUC/MPC-dependent selection of S. Typhimurium mutants in which maximum losses in
FQ susceptibility occurred at simulated AUC/MIC ratios of 71 (DIF), 63 (ENR), and 47
(MAR). AUC/MPC ratios of 69 (DIF), 62 (ENR), and 39 (MAR) were estimated to be the
minimum protective values against the selection of mutants. Generally, higher in vitro
activity of a given AUC/MIC (AUC/MPC) ratio of MAR than DIF or ENR, in terms of both
antibacterial effect and prevention of the selection of mutants, was observed. Both
target mutations (gyrA; S83F) and overexpression of efflux pumps (acrAB-tolC) upregu-
lated by global regulators contributed to these losses in susceptibility. Integration of
the MIC and MPC data with published pharmacokinetic information in pigs revealed the
inadequacy of the conventional dosing regimen of all three FQs in attaining the
above-described protective values for 90% of the mutant subpopulation (AUC/MPC90),
suggesting the need to reassess the current dosing regimens of the FQs to include both
clinical efficacy and minimization of emergence of resistant bacteria.
MATERIALS AND METHODS
Bacterial strains and antimicrobial agents. A standard strain (ATCC 14028) and 16 clinical isolates
of S. Typhimurium from diseased pigs were used. Three fluoroquinolones (FQs), including difloxacin (DIF),
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enrofloxacin (ENR), and marbofloxacin (MAR), were purchased from Sigma-Aldrich. Stock solutions (1
mg/ml in 0.1 N NaOH) were prepared and stored at 20°C. Working solutions were prepared daily from
stock solution by appropriate dilutions with the culture medium.
MIC and MPC determination. Susceptibility tests were performed before, during, and after a 3-day
course of treatment with the three FQs. The MICs were determined by the broth microdilution method
according to the CLSI (23). MICs of a quality control organism, Escherichia coli (ATCC 25922), were also
determined in parallel. MPCs were determined as described previously (9, 16). The MPC was defined as
the lowest drug concentration that completely suppressed growth for 72 h. All experiments were
performed in triplicate.
Simulated pharmacokinetic profiles. Single daily doses of the three FQs for 3 consecutive days with
simulated half-lives (t1/2) consistent with those reported in pigs were used: 12.5 h for DIF (33, 34), 10.6
h for ENR (35, 36) and 8 h for MAR (37). The doses were selected to include the achievable area under
the curve (AUC) and maximum plasma concentration (Cmax) over a 24-h dosing interval at the recom-
mended clinical doses (1 to 5 mg/kg of body weight for DIF, 2.5 to 5 mg/kg for ENR, and 2 mg/kg for
MAR) in pigs. The average ratios of the simulated AUC/MIC (averages of the values reached during 3 days)
varied from approximately 13 to 20 and 210 to 314 for the three drugs (Fig. 6). These simulated AUC/MIC
ratios corresponded to a Cmax that either equaled the MIC, fell between the MIC and MPC (i.e., within the
mutant selection window, or MSW), or exceeded the MPC.
In vitro dynamic model. A previously described dynamic model (9, 16, 22, 38, 39) was used in this
study. In brief, the model consisted of three connected flasks: a dilution compartment containing
fresh Mueller-Hinton broth II (MHB II) broth, a central compartment with either a bacterial culture
alone (control growth experiment) or a bacterial culture in medium containing drug (killing-
regrowth experiments), and an elimination compartment containing waste broth and bacteria.
Peristaltic pumps (Masterflex; Cole-Parmer, USA) circulated in one direction, from the dilution
compartment to the central compartment and from the central compartment to the elimination
compartment, at a flow rate of 3.2 ml/h for DIF, 3.9 ml/h for ENR, and 5 ml/h for MAR. The
temperature of the system was maintained at 37°C throughout the experiments. An overnight
culture of S. Typhimurium was used to inoculate the central unit. After a 2-h incubation, the resulting
exponentially growing bacterial cultures reached 107 CFU/ml (6  108 CFU per 60-ml central unit).
DIF, ENR, or MAR then was injected into the central unit. All experiments were conducted in
duplicate with 2-week intervals. The reliability of FQ pharmacokinetic simulations and the high
reproducibility of the time-kill curves provided by the model have been demonstrated previously
using several drug-pathogen combinations (9, 39). Further, the actual bacterial exposure to the FQ
was confirmed by validated high-performance liquid chromatography (HPLC) methods as described
earlier (16, 22). Pilot studies done using the reference strain and clinical S. Typhimurium strains and
two (one high and one low) simulated AUC/MIC ratios found that once the target AUC/MIC was
achieved, no strain-specific differences in the kill-regrowth kinetics were observed (data not shown).
This was in accordance with our previous studies with similar FQs and other bacterial species,
including E. coli (16). Therefore, we chose the reference strain, which is a wild-type strain with full
genomic and phenotypic characterization, to perform the experiments described below.
Quantification of the antimicrobial effect and susceptibility changes. Multiple samples of
bacterium-containing media were collected from the central compartment, and the number of bacteria
was counted throughout the experimental period. The duration of the experiments was defined in each
case as the time until FQ-exposed S. Typhimurium after the last dose reached the maximum numbers
observed in the absence of antibiotic (109 CFU/ml), and the lower limit of accurate detection was 2 
102 CFU/ml. To determine changes of susceptibility during treatment, MICs of bacterial cultures sampled
from the system were determined at 24, 48, and 72 h and compared with the initial MICs. The stability
of resistance was determined by consecutive passaging of S. Typhimurium that was exposed to drugs
through drug-free agar plates for 5 consecutive days (9, 16, 22, 38, 39).
Relationship of the antimicrobial effect to the AUC/MIC ratio. The time-kill data obtained from
the present study were converted to the intensity of the antimicrobial effect (IE), which is defined as the
area between the control growth and time-kill curves, with a cutoff level used for the regrowth and




1 exp [(x x0) ⁄ dx]
 Ymax (1)
FIG 6 In vitro simulated pharmacokinetic profiles of difloxacin (DIF), enrofloxacin (ENR), and marbofloxacin (MAR). Legends at the right indicate the AUC/MIC
values and the percentage of the dosing interval in which fluoroquinolone concentrations fall within the mutant selection window (TMSW). Daily doses of the
fluoroquinolones for 3 consecutive days were simulated.
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where Y is the IE, Ymax and Ymin are its maximum and minimum values, respectively, x is the log(AUC24/
MIC) ratio, x0 is the log(AUC/MIC) ratio that corresponds to Ymax/2, and dx is the width parameter.
Relationship of the emergence of resistance to the AUC/MIC ratio. The MIC values measured at
the end of drug exposure (MICfinal) were related to the values measured before exposing the bacterial
strains to the 3-day course of FQs (MICinitial), and the fold changes in these MICs were integrated with the
simulated AUC/MIC or AUC/MPC ratios using a Gaussian type function (16):
Y Y0 a exp  (x xc)2b  (2)
where Y is the MICfinal/MICinitial ratio, Y0 is the minimum value of Y, x is the log(AUC/MIC) or log(AUC/MPC)
ratio, xc is the log(AUC/MIC) or log(AUC/MPC) ratio that corresponds to the maximal value of MICfinal/
MICinitial, and a and b are parameters. The same equation was used to visualize the IE relationship to
resistance.
Population dynamics of fluoroquinolone treatment. In our previous studies using several bacterial
species, including E. coli and Actinobacillus pleuropneumonia, we observed the failure of high concen-
trations of FQs to clear bacteria in continuously flowing cultures (16, 24). Several mechanisms have been
proposed to contribute to these phenomena, including the presence of a persister subpopulation that
is physiologically refractory to antibiotics, the presence of an antibiotic refractory wall (biofilm) popu-
lation that is washed out at a lower rate than the planktonic and persister populations, and density-
dependent drug decay in which the effective concentration of the drug in the cultures is substantially
less than that anticipated from washout-dependent flow alone (19–21). We tested these mechanisms
using previously described methods.
The bioassay approach was used to estimate drug decay by estimating the residual FQ concen-
tration as described previously (19, 24). Briefly, medium was taken from the culture vessels every 6
h, centrifuged, and passed through 0.45-m filters (Merck Millipore, Darmstadt, Germany). The
activity of this medium against the control ATCC 14028 strain was assessed by the broth microdi-
lution method as described above and was compared with the activity of medium containing freshly
prepared drug.
Biofilm formation was evaluated by estimation of bacterial cells released from the inside walls of the
culture flasks as previously described (19, 24). Briefly, after termination of continuous culture experi-
ments, the medium was removed, the culture vessels were washed by adding an equal volume of
phosphate-buffered saline sonicated for 1 min, and the liquid was removed. This procedure was repeated
twice, after which an equal volume of MHB II was added. After 5 min of sonication at 56 kHz, the viable
cell density was estimated by culturing dilutions of the wash on agar plates.
Further, a previously described mathematical model that predicts the population dynamics of
the treated continuous culture was used to assess the contributions of different subpopulations or
drug decay to the changes in viable cell density anticipated for continuous culture experiments
(19–21, 24).
Mechanisms of resistance. To check for target mutations in quinolone resistance-determining
regions (QRDRs), genomic DNA was extracted from both clinical isolates and isolates collected from the
in vitro model, and PCR amplification was carried out using reported methods (40, 41). Sequences were
analyzed by Macrogen (Seoul, South Korea). For gene expression analysis of efflux pump and global
regulators, RNA was extracted from independent isolates and quantitative real-time PCR was performed
as described previously (25). Relative gene expression was calculated using the 2ΔΔCT method (where
the threshold cycle, CT, indicates the fractional cycle number at which the amount of amplified target
reaches a fixed threshold) (42).
Statistical analysis and curve fitting. All statistical analyses were performed using GraphPad InStat
(GraphPad Software Inc., San Diego, CA). A simulation program, Berkeley Madonna, was used for
population dynamics prediction estimation of the simulations (http://www.eclf.net). Statistical differ-
ences between groups were assessed by one-way analysis of variance (ANOVA) followed by Duncan’s
multiple-range test (version 9.4; SAS Institute, Cary, NC). Differences were considered significant at a P
value of 0.05.
Accession number(s). The sequences determined in this study were deposited in the GenBank
database under accession numbers KU325580 to KU325584, KU325564, KU325552, KU325556, and
KU325558.
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